Top Markets
#1 ADO Protocol ADO Protocol +194.54%
#2 Islamic Coin Islamic Coin +155.33%
#3 GoPlus Security GoPlus Security +40.11%
#4 GAIB AID GAIB AID +24.67%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.36%
#6 Wrapped NXM Wrapped NXM +14.17%
#7 Verus Coin Verus Coin +13.65%
#8 Casper Network Casper Network +13.15%
#9 Pons Pons +12.20%
#10 o1.exchange o1.exchange +12.20%
Coin of the day
ADO Protocol ADO Protocol
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Vascular Biogenics Ltd. Vascular Biogenics Ltd.

Vascular Biogenics Ltd.

VBLT
Classifica tra le azioni #33542
Vascular Biogenics Ltd. (VBLT) operates as a clinical-stage biopharmaceutical... Vascular Biogenics Ltd. (VBLT) operates as a clinical-stage biopharmaceutical company, dedicated to developing therapeutic solutions for cancer and immune-inflammatory diseases. The company's activities are concentrated in Israel and the United States. Its pipeline is anchored by two core technological platforms: First, a gene-based vascular targeting system that focuses on newly formed blood vessels; and second, an antibody-based monocyte targeting technology that aims to specifically inhibit monocyte migration, particularly for immune-inflammatory applications. VBLT's flagship product candidate, VB-111, a gene-based biologic, is undergoing several clinical trials. It has reached Phase III for the treatment of recurrent, platinum-resistant ovarian cancer. Additionally, it is in Phase II trials for recurrent glioblastoma and colorectal cancer. Moreover, VB-111 has completed Phase II clinical trials for thyroid cancer. The company is also developing VB-601 for a variety of inflammatory indications and VB-611 for different types of solid tumors. Initially incorporated as Medicard Ltd. in 2000, the company rebranded as Vascular Biogenics Ltd. in January 2003. Its main offices are situated in Modi'in, Israel.
Prezzo delle azioni
$0.155
Ultima sincronizzazione: 2023-10-16
Capitalizzazione di mercato
$7.44M
Variazione (1 giorno)
-9.36%
Variazione (1 anno)
0.00%
Paese
IL
Scambia Vascular Biogenics Ltd. (VBLT)

Categoria

Healthcare
Ricavi di Vascular Biogenics Ltd. (VBLT)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Vascular Biogenics Ltd., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Vascular Biogenics Ltd. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE